



**P.17019/01/2021-PvPI**  
**Indian Pharmacopoeia Commission**  
**National Coordination Centre-Pharmacovigilance Programme of India**  
**(Ministry of Health & Family Welfare, Govt. of India)**

Email: [pvpi.ipc@gov.in](mailto:pvpi.ipc@gov.in), [lab.ipc@gov.in](mailto:lab.ipc@gov.in), Website: [www.ipc.gov.in](http://www.ipc.gov.in), Tel. No. 0120-2783400

Sector-23, Raj Nagar,  
Ghaziabad-201002, U.P.  
Dated: 30<sup>th</sup> November, 2021.

### Monthly Drug Safety Alert

The preliminary analysis of Adverse Drug Reactions (ADRs) from the PvPI database reveals that the following suspected drug is associated with the ADR as given below.

Sl. No.	Suspected Drug	Indication	Adverse Drug Reaction
1.	Diclofenac	For the treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, gout, painful post-operative pain following dental surgery, migraine attack and post-operative inflammation in patients who have undergone cataract operation.	Skin hyperpigmentation

Healthcare Professionals, Patients/Consumers are advised to closely monitor the possibility of the above ADR associated with the use of above suspected drug. If such reaction is encountered, please report to the NCC-PvPI, IPC by filling of Suspected Adverse Drug Reactions Reporting Form/Medicines Side Effect Reporting Form for Consumer (<http://www.ipc.gov.in>), through Android Mobile App “**ADR PvPI App**” and **PvPI Helpline No. 1800-180-3024 (Toll Free)**.